The Heart House Roundtables address high-value topics by convening nationally recognized experts representing a wide variety of professional societies and other key stakeholders (e.g. patients, federal agencies, health plans and integrated health systems) in interactive and facilitated in-depth discussions. 

They are designed to explore the practical issues that clinicians and patients face every day and allow participants the opportunity to brainstorm possible solutions to address them. These meetings have been instrumental in informing the development of ACC-led expert consensus decision pathways and other exciting new tools and resources.

Since 2013, the ACC has held over a dozen Heart House Roundtables, to include:  

  • Anticoagulation Consortium
  • LDL: Address the Risk
  • Evolving Valve Management Strategies
  • Emerging Strategies for Heart Failure
  • Managing CV Disease Risk in Diabetes
  • Effective Prior Authorization: Right Drug, Right Patient For CV Treatment
  • Cardiovascular Function and Cancer Treatment
  • CVD Risk Communication for Patients and Their Clinicians
  • Optimizing Procedural Standards for MR and Translating Valve Standards
  • LDL & Beyond
  • Cardio-Oncology: Risk Assessment & Management Strategies
  • Type 2 MI
  • ASCVD and Multiple Comorbidities
  • Chest Pain in the Emergency Department
  • Cardiovascular Clinical Research in the COVID-19 Era
  • Telehealth: The Intersection of Technology and Health Care

The ACC would like to thank the supporters of these roundtables for their contribution to the success of these meetings:

  • Anticoagulation Consortium Roundtables: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company and Pfizer Inc.; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer; and Portola Pharmaceuticals, Inc.
  • LDL: Address the Risk Think Tanks: Amgen; CVS Health, Eli Lilly, Pfizer; Regeneron Pharmaceuticals, Inc.; and Sanofi.
  • Evolving Valve Management Strategies RoundtablesAbbott; Edwards Lifesciences; and Medtronic.
  • Emerging Strategies for Heart Failure Roundtable: Novartis
  • Managing CV Disease Risk in Diabetes Roundtables: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Novo Nordisk Inc.
  • Effective Prior Authorization: Right Drug, Right Patient for CV Treatment Roundtable: Amgen; Bristol-Myers Squibb Company and Pfizer Inc.; Janssen Pharmaceuticals, Inc.; Sanofi and Regeneron.
  • Cardiovascular Function and Cancer Treatment Roundtable: Bristol-Myers Squibb Company and Pfizer Inc., and Janssen Pharmaceuticals, Inc.
  • Optimizing Procedural Standards for MR and Translating Valve Standards Roundtable: Abbott; Boston Scientific; Edwards Lifesciences; and Medtronic.
  • LDL & Beyond: Emerging Management Strategies For Patients With Dyslipidemia Roundtable: Amgen, Amarin, Sanofi and Regeneron
  • Cardio-Oncology: Risk Assessment & Management Strategies Roundtable: Janssen Pharmaceuticals, Inc./Pharmacyclics, Inc.
  • Addressing Dilemmas Related to Type 2 MI Roundtable: Siemens Healthineers; Terarecon
  • Navigating Treatment Decisions For Patients With ASCVD and Multiple Comorbidities Roundtable: Amgen; AstraZeneca Pharmaceuticals LP; Janssen Pharmaceuticals, Inc.
  • Emergency Department of Patients with Possible ACS Roundtable: Canon Medical; GE Healthcare; HeartFlow; Siemens Healthineers; Terarecon; United Imaging
  • Cardiovascular Clinical Research in the COVID-19 Era Roundtable: Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company
  • Telehealth: The Intersection of Technology and Health Care Roundtable: Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company
  • LDL-C Lowering Therapies: The Changing Lipid Landscape: Esperion; Novartis